<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01805791</url>
  </required_header>
  <id_info>
    <org_study_id>HMPL-004-03</org_study_id>
    <nct_id>NCT01805791</nct_id>
  </id_info>
  <brief_title>A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis</brief_title>
  <official_title>A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo-Controlled Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hutchison Medipharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hutchison Medipharma Limited</source>
  <brief_summary>
    <textblock>
      A placebo controlled study of two doses of HMPL-004 in patients with active mild to moderate
      ulcerative colitis (UC), with a modified Mayo Score 4-10 and an endoscopy subscore of 2-3,
      taking mesalamine (or equivalent) as a concomitant medication.

      The objective is to evaluate the efficacy and safety of HMPL-004 with mesalamine (mesalamine
      treatment failures). Efficacy will be measured by a comparison of the proportion of patients
      in each treatment group attaining clinical remission at Week 8 as compared to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase III study of HMPL-004 was to enroll approximately 420 subjects with active mild to
      moderate ulcerative colitis (UC; modified Mayo Score 4-10 and endoscopy score of 2-3). The
      trial included male and female subjects aged 18 or older. Subjects were currently receiving
      ≥2.4 g/day mesalamine or equivalent, provided they had taken 5-aminosalicylate (ASA; i.e.,
      mesalamine) at a dose ≥2.4 g/day for at least 6 weeks prior to randomization and were on a
      stable dosage for at least 2 weeks prior to entering the screening phase of the study.

      Qualifying subjects who entered into this study received 3 daily doses of oral HMPL 004
      tablets or placebo for 56 days (8 weeks). There were 3 arms in this study consisting of
      placebo, HMPL-004 600 mg three times a day (TID) or 800 mg TID. Approximately 420 subjects
      were to be randomized 1:1:1 to one of these 3 arms, stratified by country/region in up to 150
      clinical centers in North America, Europe, and Asia.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Interim futility analysis results
  </why_stopped>
  <start_date type="Actual">March 2013</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Subjects were randomized according to a stratified blocked randomization schedule generated by an unblinded biostatistician. Stratification was by country/region and modified Mayo Score at screening using an interactive web-based response system (IWRS).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With a Clinical Remission at Week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>Clinical remission was defined as a total Mayo Score of ≤2 points with no individual sub-score &gt;1 point and rectal bleeding score = 0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Subjects With Clinical Response at Week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>Clinical response was defined as a decrease in a modified Mayo Score from baseline by ≥3 points and ≥30% decrease in the modified Mayo Score, along with either a decrease in the rectal bleeding score ≥1 or an absolute rectal bleeding score ≤1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Subjects With Mucosal Healing at Week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>Mucosal healing was defined as having normal or inactive disease using a modified Mayo Score to determine if the decrease in the modified Mayo endoscopy sub-score from baseline was ≥1 in at least 1 segment and had an absolute score ≤1 in all segments.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">201</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, oral tablets, three times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HMPL-004 1800 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 600 mg HMPL-004 tablet, 2x400 mg placebo tablets taken 3 times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HMPL-004 2400 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 x 400 mg HMPL tablets, 1 x 600 mg placebo tablet, taken 3 times per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HMPL-004 1800 mg/day</intervention_name>
    <description>Subjects randomized to the arm of HMPL-004 1800 mg/day will receive HMPL-004 600 mg TID (total dose 1800 mg/day) for 56 days (8 weeks).</description>
    <arm_group_label>HMPL-004 1800 mg/day</arm_group_label>
    <other_name>Chuan xinlian</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects randomized to the arm of Placebo will receive matching Placebo three times daily for 56 days (8 weeks).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HMPL-004 2400 mg/day</intervention_name>
    <description>Subjects randomized to the arm of HMPL-004 2400 mg/day will receive HMPL-004 800 mg TID (total dose 2400 mg/day) for 56 days (8 weeks).</description>
    <arm_group_label>HMPL-004 2400 mg/day</arm_group_label>
    <other_name>Chuan xinlian</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be currently receiving mesalamine ≥ 2.4 g/day (or the equivalent) for at
             least 6 weeks prior to randomization and on a stable dosage for at least 2 weeks prior
             to entering the screening phase of the study to ensure a stable dose is established at
             least 2 weeks prior to the endoscopic procedures.

          -  Have active mild to moderate ulcerative colitis defined by a modified Mayo Score 4-10,
             and with endoscopy score activity of 2-3 points confirmed by centrally read
             colonoscopy (within 2 weeks prior to randomization.

          -  Minimum modified Mayo endoscopy score of &gt;2 at the time of study colonoscopy.

          -  Age ≥ 18 years.

          -  Patients have no prior exposure to HMPL-004.

          -  Have adequate renal, hepatic and bone marrow function (see exclusion criteria).

          -  All fertile male and female subjects must agree to use one of the following types of
             contraception: abstinence, intrauterine device, implantable progesterone device, and
             progesterone intramuscular injection, oral contraceptive which has been started at
             least one month prior to visit one and continues for the duration of the trial,
             contraceptive patch, or condom with spermicide.

          -  Show evidence of a personally signed and dated informed consent document indicating
             that the patient (or legally acceptable representative) has been informed of all
             pertinent aspects of the trial

        Exclusion Criteria:

          1. Subjects with intolerance or adverse reactions to mesalamine (or equivalent
             medications).

          2. Diagnosed with Crohn's Disease or with lesions such as fistulas or granulomas on
             biopsy noted either in history or at baseline endoscope, which would be suspicious for
             Crohn's disease, or with a diagnosis of indeterminate colitis. Subjects with Primary
             Sclerosing Cholangitis (PSC) are excluded..

          3. Severe disease with an ulcerative colitis modified Mayo Clinic score above 10 points
             at baseline.

          4. Positive stool test for pathogens for sample taken within the previous 2 weeks prior
             to study entry.

          5. Active Clostridium difficile (C. diff) infection.

          6. Use of Inflammatory Bowel Disease related herbal supplements including but not limited
             to supplements containing andrographis and probiotics two weeks prior to study entry
             or during the study.

          7. Toxic megacolon or toxic colitis.

          8. Probable requirement for intestinal surgery within 12 weeks after the start of study
             medication.

          9. Receiving oral or rectal steroids within 1 month prior to study entry.

         10. Receiving rectal mesalamine within one week prior to study entry.

         11. Receiving azathioprine, 6-mercaptopurine, methotrexate, tacrolimus, cyclosporine, or
             other immunosuppressive therapy at the time of screening or within the preceding 6
             weeks.

         12. Receiving anti-tumor necrosis factor-α agents such as infliximab, adalimumab,
             golimumab, or certolizumab pegol at the time of screening or within the preceding 8
             weeks.

         13. Receiving other investigational drugs or biologics within 1 month or five half lives.

         14. Receiving antibiotics within 2 weeks of study entry.

         15. Hemoglobin concentration &lt; 9 g/dl.

         16. White blood cell count (WBC) below 3,000/cmm, or platelets below 100,000/cmm.

         17. Serum glutamate oxaloacetate transaminase (SGOT), serum glutamate pyruvate
             transaminase (SGPT), alkaline phosphatase &gt;2.5 upper limit of normal.

         18. Serum creatinine &gt;1.5 times upper limit of normal.

         19. Significant concurrent medical diseases including: active peptic ulcer disease;
             uncompensated congestive heart disease; myocardial infarction within the last 12
             months; unstable angina pectoris; uncontrolled hypertension; pulmonary disease
             requiring oxygen therapy.

         20. Chronic Hepatitis B or any history of Hepatitis C.

         21. Previous colonic surgery except for simple polypectomy or appendectomy. .

         22. History of cancer within the last 5 years other than resected cutaneous basal and
             squamous cell carcinomas, and in situ cervical cancer.

         23. Patients with a history of or concurrent colonic dysplasia associated with UC, except
             those with completely excised sporadic colorectal polyps.

         24. Women who are pregnant or breast feeding.

         25. Patients known to be seropositive for HIV, or who have had an AIDS defining illness,
             or a known immunodeficiency disorder.

         26. Patients with a history of tuberculosis or exposure to tuberculosis, or a history of a
             chest X-ray suspicious for tuberculosis, unless confirmed to be purified protein
             derivative (PPD) skin test negative or latent tuberculosis that has been previously
             treated.

         27. History of alcohol or drug abuse that would interfere with the ability to be compliant
             with the study procedure.

         28. Known allergy to plants of the Acanthaceae family.

         29. Unwillingness to participate in the study.

         30. Any underlying medical condition that in the Investigator's opinion will make the
             administration of study drug hazardous to the patient or would obscure the
             interpretation of adverse events.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rongjun Liu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hutchison MediPharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Management, Inc</name>
      <address>
        <city>Agawam</city>
        <state>Massachusetts</state>
        <zip>01001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>March 4, 2013</study_first_submitted>
  <study_first_submitted_qc>March 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2013</study_first_posted>
  <results_first_submitted>December 13, 2019</results_first_submitted>
  <results_first_submitted_qc>December 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 2, 2020</results_first_posted>
  <last_update_submitted>December 13, 2019</last_update_submitted>
  <last_update_submitted_qc>December 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ulcerative Colitis,</keyword>
  <keyword>UC</keyword>
  <keyword>Patients</keyword>
  <keyword>active</keyword>
  <keyword>mild</keyword>
  <keyword>moderate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo, oral tablets, three times a day
Placebo: Subjects randomized to the arm of Placebo will receive matching Placebo three times daily for 56 days (8 weeks).</description>
        </group>
        <group group_id="P2">
          <title>HMPL-004 1800 mg/Day</title>
          <description>1 600 mg HMPL-004 tablet, 2x400 mg placebo tablets taken 3 times a day
HMPL-004 1800 mg/day: Subjects randomized to the arm of HMPL-004 1800 mg/day will receive HMPL-004 600 mg 3 times daily (total dose 1800 mg/day) for 56 days (8 weeks).</description>
        </group>
        <group group_id="P3">
          <title>HMPL-004 2400 mg/Day</title>
          <description>2 x 400 mg HMPL tablets, 1 x 600 mg placebo tablet, taken 3 times per day
HMPL-004 2400 mg/day: Subjects randomized to the arm of HMPL-004 2400 mg/day will receive HMPL-004 800 mg 3 times daily (total dose 2400 mg/day) for 56 days (8 weeks).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="67"/>
                <participants group_id="P3" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Demographics and baseline characteristics are summarized in the Safety Population, by treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo, oral tablets, 3 times a day
Placebo: Subjects randomized to the arm of Placebo will receive matching Placebo three times daily for 56 days (8 weeks).</description>
        </group>
        <group group_id="B2">
          <title>HMPL-004 1800 mg/Day</title>
          <description>1 600 mg HMPL-004 tablet, 2x400 mg placebo tablets taken 3 times a day
HMPL-004 1800 mg/day: Subjects randomized to the arm of HMPL-004 1800 mg/day will receive HMPL-004 600 mg 3 times a day (total dose 1800 mg/day) for 56 days (8 weeks).</description>
        </group>
        <group group_id="B3">
          <title>HMPL-004 2400 mg/Day</title>
          <description>2 x 400 mg HMPL tablets, 1 x 600 mg placebo tablet, taken 3 times a day
HMPL-004 2400 mg/day: Subjects randomized to the arm of HMPL-004 2400 mg/day will receive HMPL-004 800 mg 3 times a day (total dose 2400 mg/day) for 56 days (8 weeks).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="66"/>
            <count group_id="B2" value="67"/>
            <count group_id="B3" value="68"/>
            <count group_id="B4" value="201"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.3" spread="16.32"/>
                    <measurement group_id="B2" value="43.9" spread="15.07"/>
                    <measurement group_id="B3" value="40.6" spread="12.33"/>
                    <measurement group_id="B4" value="43.2" spread="14.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="93"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="173"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="180"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current Smoker: Yes, No</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight, Continuous</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80.94" spread="16.00"/>
                    <measurement group_id="B2" value="79.77" spread="19.35"/>
                    <measurement group_id="B3" value="82.24" spread="21.42"/>
                    <measurement group_id="B4" value="80.99" spread="19.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height, Continuous</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172.21" spread="10.30"/>
                    <measurement group_id="B2" value="170.67" spread="9.54"/>
                    <measurement group_id="B3" value="170.28" spread="8.74"/>
                    <measurement group_id="B4" value="171.05" spread="9.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With a Clinical Remission at Week 8</title>
        <description>Clinical remission was defined as a total Mayo Score of ≤2 points with no individual sub-score &gt;1 point and rectal bleeding score = 0.</description>
        <time_frame>8 weeks</time_frame>
        <population>Analysis included only those subjects who were randomized on or prior to 16 Jun 2014 and had an opportunity to complete the 8 week treatment period. Worst case imputation imputed any missing Week 8 value as a failure.</population>
        <group_list>
          <group group_id="O1">
            <title>HMPL-004 2400 mg/Day</title>
            <description>2 x 400 mg HMPL tablets, 1 x 600 mg placebo tablet, taken 3 times a day
HMPL-004 2400 mg/day: Subjects randomized to the arm of HMPL-004 2400 mg/day will receive HMPL-004 800 mg 3 times a day (total dose 2400 mg/day) for 56 days (8 weeks).</description>
          </group>
          <group group_id="O2">
            <title>HMPL-004 1800 mg/Day</title>
            <description>1 600 mg HMPL-004 tablet, 2x400 mg placebo tablets taken 3 times a day
HMPL-004 1800 mg/day: Subjects randomized to the arm of HMPL-004 1800 mg/day will receive HMPL-004 600 mg 3 times a day (total dose 1800 mg/day) for 56 days (8 weeks).</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, oral tablets, 3 times a day
Placebo: Subjects randomized to the arm of Placebo will receive matching Placebo 3 times a day for 56 days (8 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With a Clinical Remission at Week 8</title>
          <description>Clinical remission was defined as a total Mayo Score of ≤2 points with no individual sub-score &gt;1 point and rectal bleeding score = 0.</description>
          <population>Analysis included only those subjects who were randomized on or prior to 16 Jun 2014 and had an opportunity to complete the 8 week treatment period. Worst case imputation imputed any missing Week 8 value as a failure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Subjects With Clinical Response at Week 8</title>
        <description>Clinical response was defined as a decrease in a modified Mayo Score from baseline by ≥3 points and ≥30% decrease in the modified Mayo Score, along with either a decrease in the rectal bleeding score ≥1 or an absolute rectal bleeding score ≤1.</description>
        <time_frame>8 weeks</time_frame>
        <population>Analysis included only those subjects who were randomized on or prior to 16 Jun 2014 and had an opportunity to complete the 8 week treatment period. Worst case imputation imputed any missing Week 8 value as a failure.</population>
        <group_list>
          <group group_id="O1">
            <title>HMPL-004 2400 mg/Day</title>
            <description>2 x 400 mg HMPL tablets, 1 x 600 mg placebo tablet, taken 3 times a day
HMPL-004 2400 mg/day: Subjects randomized to the arm of HMPL-004 2400 mg/day will receive HMPL-004 800 mg 3 times a day (total dose 2400 mg/day) for 56 days (8 weeks).</description>
          </group>
          <group group_id="O2">
            <title>HMPL-004 1800 mg/Day</title>
            <description>1 600 mg HMPL-004 tablet, 2x400 mg placebo tablets taken 3 times a day
HMPL-004 1800 mg/day: Subjects randomized to the arm of HMPL-004 1800 mg/day will receive HMPL-004 600 mg 3 times a day (total dose 1800 mg/day) for 56 days (8 weeks).</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, oral tablets, 3 times a day
Placebo: Subjects randomized to the arm of Placebo will receive matching Placebo 3 times a day for 56 days (8 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Subjects With Clinical Response at Week 8</title>
          <description>Clinical response was defined as a decrease in a modified Mayo Score from baseline by ≥3 points and ≥30% decrease in the modified Mayo Score, along with either a decrease in the rectal bleeding score ≥1 or an absolute rectal bleeding score ≤1.</description>
          <population>Analysis included only those subjects who were randomized on or prior to 16 Jun 2014 and had an opportunity to complete the 8 week treatment period. Worst case imputation imputed any missing Week 8 value as a failure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Subjects With Mucosal Healing at Week 8</title>
        <description>Mucosal healing was defined as having normal or inactive disease using a modified Mayo Score to determine if the decrease in the modified Mayo endoscopy sub-score from baseline was ≥1 in at least 1 segment and had an absolute score ≤1 in all segments.</description>
        <time_frame>8 weeks</time_frame>
        <population>Analysis included only those subjects who were randomized on or prior to 16 Jun 2014 and had an opportunity to complete the 8 week treatment period. Worst case imputation imputed any missing Week 8 value as a failure.</population>
        <group_list>
          <group group_id="O1">
            <title>HMPL-004 2400 mg/Day</title>
            <description>2 x 400 mg HMPL tablets, 1 x 600 mg placebo tablet, taken 3 times a day
HMPL-004 2400 mg/day: Subjects randomized to the arm of HMPL-004 2400 mg/day will receive HMPL-004 800 mg 3 times a day (total dose 2400 mg/day) for 56 days (8 weeks).</description>
          </group>
          <group group_id="O2">
            <title>HMPL-004 1800 mg/Day</title>
            <description>1 600 mg HMPL-004 tablet, 2x400 mg placebo tablets taken 3 times a day
HMPL-004 1800 mg/day: Subjects randomized to the arm of HMPL-004 1800 mg/day will receive HMPL-004 600 mg 3 times a day (total dose 1800 mg/day) for 56 days (8 weeks).</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, oral tablets, 3 times a day
Placebo: Subjects randomized to the arm of Placebo will receive matching Placebo 3 times a day for 56 days (8 weeks).</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Subjects With Mucosal Healing at Week 8</title>
          <description>Mucosal healing was defined as having normal or inactive disease using a modified Mayo Score to determine if the decrease in the modified Mayo endoscopy sub-score from baseline was ≥1 in at least 1 segment and had an absolute score ≤1 in all segments.</description>
          <population>Analysis included only those subjects who were randomized on or prior to 16 Jun 2014 and had an opportunity to complete the 8 week treatment period. Worst case imputation imputed any missing Week 8 value as a failure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>86 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>HMPL-004 2400 mg/Day</title>
          <description>2 x 400 mg HMPL tablets, 1 x 600 mg placebo tablet, taken 3 times a day
HMPL-004 2400 mg/day: Subjects randomized to the arm of HMPL-004 2400 mg/day will receive HMPL-004 800 mg 3 times a day (total dose 2400 mg/day) for 56 days (8 weeks).</description>
        </group>
        <group group_id="E2">
          <title>HMPL-004 1800 mg/Day</title>
          <description>1 600 mg HMPL-004 tablet, 2x400 mg placebo tablets taken 3 times a day
HMPL-004 1800 mg/day: Subjects randomized to the arm of HMPL-004 1800 mg/day will receive HMPL-004 600 mg 3 times a day (total dose 1800 mg/day) for 56 days (8 weeks).</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo, oral tablets, 3 times a day
Placebo: Subjects randomized to the arm of Placebo will receive matching Placebo 3 times a day for 56 days (8 weeks).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>GERD</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Rongjun Liu</name_or_title>
      <organization>Hutchison MediPharma Ltd</organization>
      <phone>+86 21 2067 3203</phone>
      <email>rongjunl@hmplglobal.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

